Stock Ticker

  • Loading stock data...

Mylan NV (NASDAQ:MYL) Rejects Teva-Takeover, Calls The Bid Undervalued

Global pharmaceutical company Mylan NV (NASDAQ:MYL) chose to reject the unsolicited buyout bid by Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). The decision was made unanimously by the current Board of Directors. Teva Undervalued Mylan The opinionated directors believe that the bid approached by Teva authorities was lackluster, in all regards. The price quoted for Mylan […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Gears To Comply With Regulatory Requirements To Acquire Mylan NV (NASDAQ:MYL)

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Wednesday announced plans to sell some of its operations that are necessary to meet regulatory formalities to purchase its competitor Mylan NV (NASDAQ:MYL). Teva Pharmaceutical has not revealed the details of operations that are put on sale for the possible acquisition. In a bid to reduce pressure for […]

Mylan NV (NASDAQ:MYL) – Immediate Support At $66 Keeps The Bulls In Control

Mylan NV (NASDAQ:MYL) opened up with a big gap of over 9% and managed to end the session with almost all the gains protected after registering a new lifetime high at $74.90. The volume surged to 42 million against the daily average of 15 million only. This spurt in both price and volume was inspired […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Pitches For Mylan For $40 bn

Much to the chagrin of the global pharmaceutical trade, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) made known its intent to acquire its rival, Mylan NV (NASDAQ:MYL) for $40 billion. The deal comes on the back of weeks of speculation that Teva would offer a buyout for Mylan. Touted to be the largest deal of the […]

Appeals Court Takes Side With Mylan NV (NASDAQ:MYL) Over Patent Issue

The previous week proved to be quite eventful for Mylan NV (NASDAQ:MYL). Reports claim that the company had taken the court’s way to protect one of its respiratory medicines that faced a stiff competition from another pharmaceutical company. What’s In For The Company: The U.S. Court of Appeals took company’s side and supported four patents […]